Patent Description:
In our bodies there is constant loss and replacement of cells in the physiological process known as homeostasis. Homeostasis ensures that when we lose cells to every day wear and tear they are replaced by newly born cells derived from stem cells. Some tissues have stem cells that supply new cells at a fast rate like skin while others like the brain have slowly dividing stem cells capable of only limited cellular replacement. As we age replacement rates in all our tissues decrease because there are fewer surviving stem cells. With less cellular replacement eventually organs are inadequately repaired and fail.

It was discovered in the <NUM>'s that Hematopoietic Stem Cells (HSCs) harvested from adult bone marrow can be used to treat leukemia after radiation or chemotherapy (Mayani <NUM>, Copelan <NUM>). Transplanted HSCs seek out bone marrow and produce new blood including both myeloid and lymphoid cells. Today bone derived HSC transplantation is effective for treatment of leukemias, severe aplastic anemia, lymphomas, multiple myeloma and immune deficiency disorders among others. There are now over <NUM>,<NUM> transplantations per year worldwide (Von Ah et al. Bone marrow blood banking and human leukocyte antigen (HLA) matching enables patients to draw upon a larger donor pool thereby further expanding the effectiveness of HSC-transplantation therapy.

Adult bone marrow contains another important type of stem cell known as Mesencyhymal Stem Cells (MSCs). Although first isolated from bone marrow MSCs represent only a small fraction of total bone marrow cells. Fortunately MSCs are more prevalent in other tissues including fat, teeth and umbilical cords. MSCs are multipotent giving rise to a broad range of cell types but primarily form bone and connective tissue cells (Gonzalez et al. <NUM>, Pittenger et al. MSCs are useful in treating joint and connective tissue injuries where repair is often limited due to a lack of blood supply. When MSCs are transplanted into joints and other connective tissues they recruit blood vessels into the vicinity thereby enhancing repair.

It is now appreciated that MSCs also enhance injury repair by significantly reducing inflammation (Gonzalez et al. MSCs reduce inflammation in several ways. MSCs avoid provoking an immune response by expressing neither class I nor class II major histocompatibility proteins (MHC) (De Miguel et al. MSCs also express inflammation reducing proteins including interleukin (IL) <NUM>, IL-<NUM>, IL-<NUM>, prostaglandin E2 (PGE2), HLA-G and transforming growth factor (TGF) β1 (DeMiguel et al. <NUM>, Gonzalez et al. <NUM>, Aggarwal <NUM>). The presence of these and other factors secreted by MSCs induces nearby cells to also produce antiinflammatory factors and to reduce expression of pro-inflammatory factors such as IL-<NUM>, and tumor necrosis factor alpha (TNFα) (Gonzalez <NUM> et al.

An increasingly prevalent source of both HSCs and MSCs is human umbilical cords. Umbilical cord derived stem cells (UCSCs) are an attractive alternative to BMSCs because they are more potent, having greater proliferation and differentiation potential due to their fetal origin. UCSCs are also more cost effective to harvest compared to BMSCs. The umbilical cord in a full term baby averages <NUM> millimeters in length and about <NUM> millimeters in diameter. The outer most cord tissue is known as the amniotic epithelium. It forms a tube which contains collagen fibers, fibroblast cells, and Wharton's jelly, (a gelatinous substance made largely from mucopolysaccharides and extracellular matrix) as well as two arteries, a vein and allantois duct. Both HSCs and MSCs can be extracted from these structures having been found in cord blood, the vein, arteries, the amniotic epithelia, endothelium and Wharton's jelly (Subramanian et al.

The present invention relates to umbilical cord lining derived MSCs which are isolated from the amniotic epithelia including but not limited to ULSCs isolated by the method described in <CIT>.

<CIT>- Umbilical Cord Lining Stem Cells And Methods And Material For Isolating And Culturing Same.

<CIT>-Isolation of human umbilical cord blood-derived mesenchymal stem cells-.

<CIT>-Isolating method for umbilical cord blood-derived pluripotent stem cells expressing znf281.

<CIT>-Differentiation of stem cells from umbilical cord matrix into hepatocyte lineage cells.

<CIT>- Umbilical Cord Stem Cell Composition & Method of Treating Neurological Diseases.

<CIT> -Islet cell cluster produced from human umbilical cord mesenchymal stem cells. The invention also provides a method for using a stem cell conditioned medium to culture animal cells.

<CIT>-Buensuceso-Induced pluripotent stem cells from human umbilical cord tissue-derived cells.

<CIT>- Erythroid production - This invention provides method and media suitable for inducing and supporting the differentiation of stem cells into erythroid cells.

<CIT>-Methods for producing enucleated erythroid cells derived from pluripotent stem cells.

<CIT>- Methods of Regulating Skin Appearance with Vitamin B3 compound.

The present invention provides methods of using ULSCs.

Non-limiting examples of applications of ULSCs according to the methods herein include production of glycosaminoglycans (GAGs).

In a particular embodiment, Embodiment <NUM>, the invention provides a method of using umbilical cord lining stem cells (ULSCs) to produce glycosaminoglycans, the method comprising:.

In another embodiment, Embodiment <NUM>, the invention may provide a method according to Embodiment <NUM> wherein the glycosaminoglycans are selected from one or more of hyaluronic acid and chondroitin sulfate.

In another embodiment, Embodiment <NUM>, the invention may provide a method according to Embodiment <NUM> wherein the hyaluronic acid has a molecular weight of at least <NUM> kD.

In a final embodiment, Embodiment <NUM>, the invention may provide a method of any one of Embodiments <NUM> to <NUM> comprising the further step of purifying glycosaminoglycans.

The present invention achieves its objects by methods of propagating ULSCs that produce accumulations of glycosaminoglycans (GAGs) in conditioned media and within the cell layer that may be harvested for therapeutic uses. The manners in which the invention achieves its objects and other objects which are inherent in the invention will become more readily apparent when reference is made to the accompanying drawings.

Various embodiments of the invention are described in detail and may be further illustrated by the provided examples. As used in the description herein and throughout the claims that follow, the meaning of "a," "an," and "the" includes the plural reference unless the context clearly dictates otherwise.

Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

Terms used in this specification generally have their ordinary meanings in the art, within the context of the invention, and in the specific context where each term is used. Certain terms that are used to describe the invention are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions and methods of the invention and how to make and use them. For convenience, certain terms may be highlighted for example using italics and/or quotation marks. The use of highlighting has no influence on the scope and meaning of a term; the scope and meaning of a term is the same, in the same context, whether or not it is highlighted. It will be appreciated that the same thing can be said in more than one way. Consequently, alternative language and synonyms does not exclude the use of other synonyms. The use of examples anywhere in this specification, including examples of any terms discussed herein, is illustrative only, and in no way limits the scope of the invention so long as the data are processed, sampled, converted, or the like according to the invention without regard for any particular theory or scheme of action.

Further, whenever the name of a specific growth factor, cytokine, chemokine or extracellular matrix component is given, it is assumed to include all homologues, family members and splice variants of that factor which may also be present.

In all of the following examples, of which Example <NUM> represents a non-limiting preferred embodiment of the invention and Examples <NUM>, <NUM> and <NUM> are not according to the invention but are present for illustration purposes only, pure ULSC cell lines obtained according to prior art methods (<CIT>) and BMSC lines are propagated based upon the following protocol. Culture vessels are seeded with cells at density of 1x10<NUM> cells per cm<NUM> in Dulbecco's Modified Eagle Medium (DMEM) with low glucose and <NUM>% fetal bovine serum (FBS), hereafter referred to as expansion media. Every <NUM> days the expansion media is replaced with fresh sterile expansion media. ULSCs are allowed to grow in a CO<NUM> incubator at <NUM> until they reach <NUM>-<NUM>% confluency. Once confluent the media is replaced with sterile conditioning media consisting of <NUM>% Roswell Park Memorial Institute Medium (RPMI), <NUM>% FBS, <NUM> milliliter (ml) 100x Penicillin and Streptomycin, <NUM> 100x Non Essential Amino Acids (NEAA), <NUM> 100x Modified Eagle Medium (MEM), <NUM> Insulin, Transferrin, Selenium (ITS) supplement, <NUM> 100x Glutamine supplement. Conditioned media is collected at regular intervals into a sterile polyethylene terephthalate (PET) container that is stored at -<NUM> and replaced with fresh sterile conditioning media. The process of collecting conditioned media by this method may be continued indefinitely.

Where applicable in the examples conditioned media may be purified and concentrated according to the following protocol. Collected conditioned media is thawed at <NUM>. Collected lots are pooled and then filtered with a <NUM> micron (um) filter. Filtered conditioned media is added to sample filter centrifugation cup which is then added to the filtrate collection cup and the combination is placed in a balanced centrifuge. The centrifuge is spun at up to 3500xg until a desired concentration is obtained, typically between <NUM>-<NUM> minutes. Concentrated media may then be transferred from the filtrate collection cup for further application as desired.

Media from ULSCs, two sets from passage <NUM> and two sets from passage <NUM>, in both expansion and conditioned media and four identical cultures of BMSCs were assayed for the presence of cytokine and chemokine proteins by quantitative multiplexed immunoassay analysis (MAPs). The cytokines and chemokines profiled included: GM-CSF, INF-γ, IL-<NUM>, IL-<NUM>, IL-<NUM>, IL-<NUM>, IL-<NUM>, IL-<NUM>, MIP-1β, MCP-<NUM>, TNF-α. The MAPs analysis is based upon a capture-sandwich wherein capture antibodies are attached to fluorescently encoded microspheres. After capture of antigen from a biological sample such as cell culture media the antigen is detected and quantified using specific detection antibodies coupled to a fluorescent probe. Results obtained from this analysis were given as weight per volume of each analyte. The results were then normalized per number of cells from the corresponding well.

The results in <FIG> demonstrate that ULSCs express and secrete considerably more GM-CSF, IL-<NUM>, IL-<NUM>, IL-<NUM>, MIP-1β, MCP-<NUM>, and TNF-α than BMSCs. ULSCs express all the factors made by BMSCs and at least seven more factors not found at significant levels in BMSCs, These results are indicative but not exhaustive of the cytokines and chemokines which may be present in ULSCs conditioned media and cell culture tissue. Other cytokines which may be present include those from all four cytokine families: the four α-helix bundle family (the IL-<NUM> subfamily, the interferon subfamily, the IL-<NUM> subfamily), the IL-<NUM> family (primarily IL-<NUM> and IL-<NUM>), the IL-<NUM> family and the cysteine-knot family (transforming growth factor beta superfamily including TGF-β1, TGF-β2, TGF-β3). Other chemokines which may be present include those from all four classes including C chemokines (XCL1 and XCL2), CC chemokines (CCL1-CCL28), CXC chemokines (CXCL1-CXCL17), CX3C chemokines (CX3CL1).

Conditioned media obtained from ULSCs and BMSCs was assayed for the presence of VEGF and SCF proteins by an Enzyme Linked Immunosorbent Assay (ELISA). Conditioned media was collected from a total of <NUM> cultures, two sets of ULSCs and two sets of BMSCs at <NUM>, <NUM>, and <NUM> days. Controls tested included <NUM>% FBS media, <NUM>% FBS media, <NUM>% media plus vitamin B3, ULSCs in chondro media, and ULSCs in a transwell plate with a chondrocyte pellet. Concentrated conditioned media from each sample was added to each ELISA test strip well and incubated for one hour with gentle shaking. The ELISA strip was washed with assay buffer to stop the reaction and the optical density of each ELISA strip well was measured with a microplate reader at <NUM>.

The results in <FIG> demonstrate that SCF is expressed and secreted at a considerably higher level in both sets of ULSCs at all time points compared to both sets of BMSCs. The results also show that both ULSCs and BMSCs express significant levels of VEGF but that after <NUM> days BMSCs secrete less VEGF than ULSCs. These non-limting examples are indicative but not exhaustive of the growth factors which may be present in ULSCs conditioned media and cell culture tissue. Other growth factors which may be present include VEGF family proteins, Epidermal Growth Factor (EGF) family proteins, Fibroblast Growth Factor (FGF) family proteins, Transforming Growth Factor beta (TGF-β) family proteins, Angiopoietin family proteins, Brain Derived Neurotrophic factor family proteins.

Media was collected from both ULSCs and BMSCs either daily or every third day from cell cultures propagated in either growth media or conditioning media. The cell layers in each well were also analyzed. The filtered and concentrated media is treated with proteases and nucleases to remove protein and nucleic acid, then treated with detergent and alcohol to remove lipids, leaving a mixture enriched with complex carbohydrates including glycosaminoglycans (GAGs). The GAGs mixture was then treated with a hyaluronidase enzyme which cleaves the GAGs into their constituent parts. The hyaluronic acid fragments were then separated by either polyacrylamide gel electrophoresis (PAGE) or agarose gel electrophoresis.

In <FIG>, the cleaved GAGs were treated with mercuric ion, and then tagged by reductive amination giving an identical fluorescent signal for every free reducing group. The fluoro-tagged products were then separated by PAGE and scanned by CCD camera then analyzed with quantitative image analysis software. The results shown here demonstrate the presence of significant levels of HA and CS in the conditioned media of both ULSCs and BMSCs. These non-limiting examples are indicative but not exhaustive of the extracellular matrix constituents which may be present in ULSCs conditioned media and cell culture tissue. Other extracellular matrix constituents which may be present include: heparan sulfate, keratin sulfate, elastin fibers, fibronectins and laminins.

In <FIG>, the cleaved GAGs were then separated on an agarose gel and stained for visualization prior to imaging. The results in <FIG> demonstrate that a considerable fraction of the HA present is in the media of both ULSC and BMSC cultures is high molecular weight up to at least <NUM> kD. When further digested with Hyase (<FIG>), HA accumulates in low molecular weight fragments at the bottom of the gel.

<FIG> provides a quantitation of the amounts of HA and CS present in both ULSC and BMSC cells and conditioned media. ULSC cells have increased quantities of both HA and CS compared to BMSCs and in conditioned media ULSCs produced more CS than BMSCs whereas HA levels were similar.

Collagen standards are prepared at <NUM><NUM>, <NUM>-<NUM>, <NUM>-<NUM>, <NUM>-<NUM> and <NUM>-<NUM> dilutions from <NUM>/ ml stock in phosphate buffered saline. Ten microliters of ULSC conditioned media is used to make Collagen samples in triplicate. Sample A is cell culture medium supplemented with <NUM> % fetal bovine serum and <NUM> % ITS conditioned for <NUM> days by confluent ULSCs. Sample B is sample A concentrated <NUM> fold by centrifugation filter. Sample C is sample B filtered through <NUM> Whatman paper. The test samples are deposited in a well of a <NUM>-well cluster, and air-dried. Sample A is tested as <NUM><NUM>, and <NUM>-<NUM> dilutions; samples B and C are tested as <NUM><NUM>, <NUM>-<NUM>, <NUM>-<NUM>, and <NUM>-<NUM> dilutions. One hundred microliters Bouin's fluid were added to each well and incubated at <NUM>, for <NUM> hour, in a humidified enclosure. The Bouin's fluid was removed by aspiration, and the well was washed five times, each time with <NUM>µl deionized water, and air-dried. Seventy five microliters working Sirius Red solution were added to each well, and also to a set of <NUM> empty wells, serving as background controls, and incubated at <NUM>, for <NUM> hour, in a humidified enclosure. The dye solution was removed by aspiration, and the well was washed five times, each time with <NUM>µl deionized water, and air-dried. One hundred microliters of <NUM> N NaOH were added to each well and agitated for <NUM> hours at ambient temperature. Absorbance at <NUM> (A <NUM>) was determined using a microtiter plate reader. Standard collagen amounts were plotted vs. the average A-<NUM> values to produce a standard curve with best fit equation of two variables. One average A-<NUM> value of each conditioned medium sample was selected to substitute for the abscissa variable, to yield the ordinate value, which was corrected for the dilution factor and the volume of material used for testing (<NUM>µl) to give the estimated collagen concentration in the original conditioned medium.

Claim 1:
A method of using umbilical cord lining stem cells (ULSCs) to produce glycosaminoglycans, the method comprising:
a. Propagating ULSCs in a growth media or conditioning media;
b. Filtering and concentrating the growth media or conditioning media from step a.;
c. Treating the filtered and concentrated growth media or conditioning media from step b. with proteases and nucleases to remove protein and nucleic acid;
d. Treating the treated growth media or conditioning media from step c. with a detergent and an alcohol to remove lipids;
e. Harvesting glycosaminoglycans from the treated growth media or conditioning media from step d.